years, the progressive replacement of EUS-FNA with EUS guided-fine needle biopsy (EUS-FNB) was noted due to the introduction of several specially designed needles that provide core tissue samples that allow for histological assessment. The EchoTip ProCore (Cook Medical, Winston-Salem, NC, USA) needle has a reverse bevel design and the EZ shot 3 plus needle (Olympus America Inc., Lombard, IL, USA) has a flexible coil sheath that allows for precise and smooth penetration into the target lesion. The SharkCore (Medtronic, Minneapolis, MN, USA) needle has a fork-tip design with 2 leading sharp tips and the Acquire needle (Boston Scientific Co., Natick, MA, USA) has a Franseen tip design with 3 symmetrical cutting surfaces. 5 When compared with conventional ultrasound and computed tomography scan, EUS showed superiority in the detection and sampling of liver lesions. In a recent review of 9 published studies (6 prospective, 2 retrospective, and 1 observational), the diagnostic accuracy of tissue sampling of liver lesions via EUS-FNA and/or FNB ranged from 80% to 100%. 6 In this issue, Eskandari et al. 7 compared the performance of 6 needles with different gauges (SharkCore 19 and 22 G, Acquire 19 and 22 G, EZ Shot 3 Plus 19 G, and EchoTip ProCore 20 G) for EUS-guided liver biopsy on a freshly harvested bovine liver. All the 19 and 20 G needles yielded similar mean numbers of complete portal tracts (CPTs) and were significantly superior to the SharkCore 22 G needle. The outcomes with the large bore needles were significantly superior to that with the 22 G SharkCore needle. No statistically significant difference in the total specimen length was found among the three 19 G needles and the 20 G needle tested. The performance of the two 22 G needles was similar (number of CPTs, mean fragment length, and mean specimen length). In this same issue, Chon et al. 8 studied the safety, efficacy, and outcomes of EUS-FNB using a core needle (EchoTip ProCore HD ultrasonography-guided biopsy needle) in 58 hepatic solid masses (46 metastatic and 16 non-metastatic lesions). The metastatic lesions included 38 metastatic pancreatic cancer lesions, 4 metastatic ampullary cancer lesions, and 4 meta-static lung cancer lesions. The non-metastatic lesions included 9 cholangiocarcinomas and 3 hepatocellular carcinomas. The diagnostic accuracy was 89.7%. The sensitivity and specificity were 89.7% and 100%, respectively. The analysis of factors that could affect the diagnostic accuracy of EUS-FNB for hepatic solid masses revealed no significant associations. The factors assessed included the number of needle passes, needle gauge, needle approach route (transgastric or transduodenal), and mass size. Both studies have several limitations. The first study was performed on an ex vivo liver model; thus, adverse events could not be evaluated, and a real-time tissue evaluation may be affected by anatomical and technical variations. The second study was retrospective, with a relatively small sample size and possibly underreported adverse events.
At our facility and on the basis of the increasing evidence supporting the use of FNB for sampling solid lesions and performing targeted biopsies, we have gradually adopted FNB as a replacement for FNA for the sampling of solid lesions. This approach has the advantages of fewer number of passes and shorter overall procedure time. 4 We strongly believe that future needle platforms will adopt an improved tip design for better access and enhanced core retention to optimize EUS-TA. The main question remains whether the available literature provides enough evidence to support the use of EUS-FNA and/or EUS-FNB for liver lesions as a replacement for percutaneous liver biopsy, which has been considered the gold standard for many years. Further studies are needed to address this concern.
